Oral dydrogesterone versus intravaginal micronised progesterone as luteal phase support in assisted reproductive technology (ART) cycles: Results of a randomised study
Oral dydrogesterone versus intravaginal micronised progesterone as luteal phase support in assisted reproductive technology (ART) cycles: Results of a randomised study
复制标题
DOI：
10.1016/j.jsbmb.2005.08.012
复制
发表时间：
2005-12-01
影响因子：
4.1
通讯作者：
Ghosh, S
中科院分区：
文献类型：
--
作者：
Chakravarty, BN;Shirazee, HH;Ghosh, S
这项前瞻性随机研究的目的是比较阴道微孕酮与口服地孕酮作为体外受精（IVF）后黄体期支持的疗效、安全性和耐受性。共有430名妇女接受了体外受精/胞浆内单精子注射（ICSI）治疗。长期方案促性腺激素释放激素类似物下调后，促性腺激素刺激。当两个或两个以上卵泡达到>= 17 mm时给予人绒毛膜促性腺激素。36 h后取出卵母细胞，进行体外受精。胚胎移植在4-8细胞胚胎期进行。黄体支持从胚胎移植之日起开始，持续14天。患者被随机分配到黄体补充组：阴道内微孕酮200mg，每日3次（n = 351）或口服地屈孕酮10mg，每日2次（n = 79）。在妊娠试验阳性的情况下，黄体支持持续12周。地屈孕酮和微孕酮与成功怀孕的几率相似。服用微孕酮的患者中有10.5%报告阴道分泌物或刺激。服用地屈孕酮的患者对治疗耐受性满意的比例明显高于服用微孕酮的患者（p < 0.05）。在肝功能测试方面，两种治疗方法之间没有差异。(c) 2005 Elsevier Ltd版权所有。
The objective of this prospective, randomised study was to compare the efficacy, safety and tolerability of vaginal micronised progesterone with oral dydrogesterone as luteal phase support after in-vitro fertilisation (IVF). A total of 430 women underwent IVF/intracytoplasmic sperm injection (ICSI) treatment. Long protocol gonadotropin releasing hormone analogue down-regulation was followed by gonadotropin stimulation. Human chorionic gonadotropin was given when two or more follicles reached >= 17 mm. After 36 h, oocytes were retrieved and IVF was performed. Embryo transfer was done at the 4-8 cell embryo stage. Luteal support was initiated from the day of embryo transfer and continued for up to 14 days. Patients were randomised to luteal supplementation with either intravaginal micronised progesterone 200 mg three times daily (n = 351) or oral dydrogesterone 10 mg twice daily (n = 79). In cases of a positive pregnancy test, luteal support was continued for 12 weeks. Both dydrogesterone and micronised progesterone were associated with similar rates of successful pregnancies. Vaginal discharge or irritation were reported by 10.5% of patients given micronised progesterone. Significantly (p < 0.05), more patients given dydrogesterone than micronised progesterone were satisfied with the tolerability of their treatment. There were no differences between the treatments with regard to liver function tests. (c) 2005 Elsevier Ltd. All rights reserved.